| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2575764 | The American Journal of Geriatric Pharmacotherapy | 2011 | 5 Pages |
Abstract
The initial choice among the various cholinesterase inhibitors requires consideration to adherence and cost. Consideration to differences in pharmacokinetics among these drugs provides a better understanding for the clinical practice of dose titration, identification and management of drug-related side effects, and lapses in therapy. Pharmacokinetic considerations among the various agents and formulations provide the clinician with options to enhance therapy when these agents are chosen for treatment of patients with Alzheimer-type dementia.
Related Topics
Health Sciences
Medicine and Dentistry
Geriatrics and Gerontology
Authors
Irving H. MDCM, Candace PharmD, Thomas M. PhD,